



Inhibiting Quorum Sensing in *Staphylococcus Epidermidis*, a Health Care Pathogen

[View U.S. Patent No. 12,662,513 in PDF format.](#)

WARF: P150348US02

Inventors: Helen Blackwell, Tian Yang

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in the first synthetic – and most potent – QS inhibitors reported to date for *S. epidermidis*. These compounds represent powerful tools for modulating virulence and for research into this emerging public health threat.

Overview

Staphylococcus epidermidis is an important Gram-negative bacterial pathogen in hospital-acquired infections, and the most common cause of infections on indwelling medical devices. **The costs related to vascular catheter-related bloodstream infections caused by *S. epidermidis* are estimated at \$2 billion annually in the U.S. alone.** Treatment of *S. epidermidis* infection is complicated by multidrug resistance and persistent biofilm formation.

Bacterial quorum sensing (QS) plays a key role in infection, and targeting this system with pharmacotherapies could significantly attenuate virulence.

The Invention

UW–Madison researchers have synthesized a set of potent peptidic modulators of *Staphylococcus epidermidis* quorum sensing. Targeting the AgrC receptor, these compounds include the first universal QS inhibitors active against all known groups of *S. epidermidis*. Others are strongly group- or species-selective and could be applied to selectively modulate either *S. epidermidis* or *S. aureus* quorum sensing.

Applications

- Modulating virulence and inhibiting biofilm growth
- Research tool

Key Benefits

- First and most potent synthetic QS inhibitors of their kind
- *S. epidermidis* infections resist traditional antimicrobial treatment and pose a serious public health burden.

Stage of Development

Several inhibitors have been tested and shown to strongly antagonize or agonize the AgrC-I receptor. Notably, one compound was found to strongly inhibit *S. epidermidis* biofilm growth, with a higher potency and efficacy than the native autoinducing peptide.

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

For More Information About the Inventors

OK



WARF
Wisconsin Alumni Research Foundation

| info@warf.org | 608.960.9850

- [Helen Blackwell](#)

Related Technologies

- [Find more anti-quorum sensing agents developed by Prof. Helen Blackwell.](#)

Tech Fields

- [Therapeutics & Vaccines : Anti-infectives \(antibacterials, antifungals, antivirals\).](#)

For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

OK



WARF
Wisconsin Alumni Research Foundation

| info@warf.org | 608.960.9850